Johnson & Johnson

09/08/2024 | Press release | Distributed by Public on 09/08/2024 11:48

RYBREVANT® (amivantamab vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR mutated advanced lung cancer